β-阻断剂作为高血压管理治疗的第一线治疗
Saumitra Ray1, Saboo Banshi2, Joshi Shashank3
1Director of Invasive Cardiology, Department of Cardiac Sciences, AMRI Hospital, Kolkata, West Bengal, India, Corresponding Author.
概括
β抑制剂 (BBs) 正在重新出现,成为高血压 (HTN) 的首选一线治疗方法. 最近的指导方针支持它们的使用,即使在复杂的病例中,也挑战了治疗建议的先前降级.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 贝塔抑制剂 (BBs) 从历史上来看是高血压 (HTN) 和相关疾病 (如缺血性心脏病和心律失常) 的首要选择.
- 充血性心力衰竭,曾经是一种禁忌,现在是BBs的确立指示.
- 新型抗高血压药物的出现导致BBs在治疗指南中被降级,尽管存在现实数据和对试验方法的担忧.
研究的目的:
- 重新评估β阻塞剂 (BBs) 在当代高血压管理中的作用.
- 根据可能有缺陷的比较试验设计,解决BBs的历史降级问题.
- 要突出最近的指导方针转变,支持BBs作为一线治疗.
主要方法:
- 对高血压 (HTN) 中β-阻断剂 (BBs) 的历史使用和临床试验数据的审查.
- 分析欧洲高血压学会 (ESH) 最近的指导方针及其建议.
- 检查真实世界的数据和临床医生对BB疗效的观点.
主要成果:
- 对于导致BBs降级的试验的设计和解释提出了担忧.
- 承认并非所有BBs在药理上都是相似的,质疑全面的降级.
- 最近的ESH指南将BB恢复为一线抗高血压药物,适合与其他类别互换使用.
结论:
- 贝塔抑制剂 (BBs) 现在被认为是高血压 (HTN) 管理的有价值的第一线药物,得到了更新的指南的支持.
- 该ESH指南包括十九个额外的条件,其中BBs是首选的,如高心率 (HR),COPD和阻塞性睡眠呼吸暂停.
- β抑制剂已经完成了高血压治疗的完整周期,建议在黄金时段使用.
相关概念视频
01:28Antihypertensive Drugs: Types of β-Blockers
657
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
657
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
783
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
783
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
592
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
592
01:17Antihypertensive Drugs: Action of β1 Blockers
434
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
434
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442